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Thesis Abstract 
Cancer is still the leading cause of human morbidity and mortality 
worldwide, with increasing incidence because of changing lifestyle and increased 
exposure to carcinogens. Most of the available treatments like surgery, 
chemotherapy, and radiotherapy are associated with undesirable side effects. 
Thus, explore for more selective anti-cancer strategy should be urgently required. 
Hyperthermia (HT) is a promising therapeutic tool which acts by directly 
damaging and killing cancer cells or enhancing the efficacy of other existing 
cancer treatment modalities (e.g. radiotherapy, chemotherapy, etc.) against 
various cancer types, with minimal injury to normal cells. However, the efficiency 
of hyperthermia treatment is related to the temperature achieved during the 
heating, the exposure time, and tumor cell characteristics. Therefore, in many 
circumstances, its cytotoxic effect is often insufficient for quantitative cancer cell 
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death because of these biological and technical problems. To overcome these 
challenges, several studies have explored non-toxic enhancers for HT-induced cell 
death. Here we employed HT as an adjuvant therapy with cold atmospheric 
helium plasma (He-CAP), which produces an enormous amount of reactive 
oxygen species (ROS) in the liquid phase, and an anti-inflammatory drug, 
5-aminosalicylic acid (5-ASA) that clinically use in the treatment of inflammatory 
bowel disease (IBD). In this study, we addressed how HT enhances He-CAP and 
5-ASA induced cell death in various cancer cells. Combined treatment of HT with 
He-CAP and 5-ASA significantly enhanced apoptosis and cytotoxicity in cancer 
cells, but not in normal cells. Furthermore, the combination was associated with 
increases of reactive oxygen and nitrogen species (ROS/RNS) generation, 
endoplasmic reticulum (ER) stress marker proteins expression, intracellular 
calcium [Ca2+]i concentrations. Apoptotic endpoints were significantly increased 
by the combination treatment, as evidenced by the presence of 
Annexin-V/PI-positive cells, loss of mitochondrial membrane potential, Bcl-2/Bax 
ratio alteration, increase in the expression levels of the death receptor Fas and 
cleaved Bid, and caspase activation. Interestingly, the enhancement of apoptosis 
was reversed in the presence of ROS/RNS scavengers. These findings indicate that 
the HT in combination with He-CAP and 5-ASA synergistically enhances apoptosis 
via ROS/RNS-mediated ER stress-Ca2+-mitochondria signaling and 
caspase-dependent apoptotic pathways. Our findings provide novel evidence that 
HT could be an enhancing agent for the physical modality (He-CAP) and chemical 
modality (5-ASA) in various tumors. More importantly, it reveals that increased 
ROS/RNS generation might be an effective strategy in treating human cancer. In 
conclusion, this work provides evidence for the novel anti-cancer strategy which 
might be used for the treatment of cancer in the future and further in vivo studies 
are needed. 
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